SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Financials Shanghai Allist Pharmaceuticals Co., Ltd.
Equities
688578
CNE100005XJ7
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.6 CNY | +0.03% |
|
-7.08% | +43.06% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,816 | 13,590 | 8,856 | 18,747 | 26,820 | - | - |
| Enterprise Value (EV) 1 | 12,816 | 13,590 | 8,856 | 18,747 | 26,820 | 26,820 | 26,820 |
| P/E ratio | -33.9 x | 755 x | 65.6 x | 29.1 x | 25.9 x | 22 x | 16.8 x |
| Yield | - | - | - | 0.96% | 0.84% | 0.84% | - |
| Capitalization / Revenue | 22,849 x | 25.6 x | - | 9.32 x | 9.06 x | 7.76 x | 6.11 x |
| EV / Revenue | 22,849 x | 25.6 x | - | 9.32 x | 9.06 x | 7.76 x | 6.11 x |
| EV / EBITDA | - | - | - | 27 x | 25.2 x | 20.3 x | 16.3 x |
| EV / FCF | - | - | - | 30,896,517 x | - | - | - |
| FCF Yield | - | - | - | 0% | - | - | - |
| Price to Book | 4.45 x | 4.57 x | - | 4.69 x | 5.54 x | 4.66 x | 3.63 x |
| Nbr of stocks (in thousands) | 450,000 | 450,000 | 450,000 | 450,000 | 450,000 | - | - |
| Reference price 2 | 28.48 | 30.20 | 19.68 | 41.66 | 59.60 | 59.60 | 59.60 |
| Announcement Date | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.5609 | 530.1 | - | 2,012 | 2,961 | 3,455 | 4,389 |
| EBITDA 1 | - | - | - | 695.4 | 1,066 | 1,318 | 1,642 |
| EBIT 1 | -310.5 | 21.83 | - | 660.7 | 1,076 | 1,327 | 1,702 |
| Operating Margin | -55,348.85% | 4.12% | - | 32.83% | 36.36% | 38.41% | 38.79% |
| Earnings before Tax (EBT) 1 | -310.5 | 18.27 | - | 659.2 | 1,074 | 1,324 | 1,700 |
| Net income 1 | -310.5 | 18.27 | 133 | 644.9 | 1,037 | 1,220 | 1,598 |
| Net margin | -55,360.17% | 3.45% | - | 32.04% | 35.02% | 35.32% | 36.4% |
| EPS 2 | -0.8400 | 0.0400 | 0.3000 | 1.430 | 2.305 | 2.710 | 3.550 |
| Free Cash Flow | - | - | - | 606.8 | - | - | - |
| FCF margin | - | - | - | 30.15% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | 87.25% | - | - | - |
| FCF Conversion (Net income) | - | - | - | 94.09% | - | - | - |
| Dividend per Share 2 | - | - | - | 0.4000 | 0.5000 | 0.5000 | - |
| Announcement Date | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | 607 | - | - | - |
| ROE (net income / shareholders' equity) | -25.3% | 0.62% | - | 18% | 21.5% | 21.7% | 21.7% |
| ROA (Net income/ Total Assets) | - | - | - | 14.7% | 20.1% | 20.5% | 21.1% |
| Assets 1 | - | - | - | 4,384 | 5,159 | 5,953 | 7,571 |
| Book Value Per Share 2 | 6.400 | 6.610 | - | 8.890 | 10.80 | 12.80 | 16.40 |
| Cash Flow per Share 2 | -0.4400 | 0.0700 | - | 1.500 | 1.930 | 2.400 | 3.110 |
| Capex 1 | - | - | - | 67.9 | 87 | 87 | 75 |
| Capex / Sales | - | - | - | 3.37% | 2.94% | 2.52% | 1.71% |
| Announcement Date | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
59.6
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +43.06% | 3.71B | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- 688578 Stock
- Financials Shanghai Allist Pharmaceuticals Co., Ltd.
